Search for a trial

Diarrhea during use of the oral angiogenesis inhibitors sunitinib and sorafenib

To identify what might be the cause of the occurrence of diarrhea during the use of angiogenesis inhibitors sunitinib and sorafenib in patients with a malignancy.

Impact of new approaches to pharmacological management of patients with renal cell carcinoma: a population-based study of process and outcomes in The Netherlands

The 1st main objective is to collect detailed quantitative data on the everyday management of mRCC in the Netherlands, the clinical outcome of this management, as well as the resulting quality of life and financial costs. Treatment selection for…

EuroTARGET: European collaborative project on TArgeted therapy in Renal cell cancer: GEnetic and Tumour-related biomarkers for response and toxicity

This project aims to identify and characterize host and tumour related biomarkers and to predict responders and/or adverse responders from non-responders for targeted therapy in mRCC. Our overall concept is to focus on germline genome and tumour…

Evaluation of cognitive function of patients treated with sunitinib or sorafenib (UMCONCO200904

Tot evaluate the cognitive function of patients treated with sunitinib or sorafenib for metastatic renal cell cancer or a GIST, in order to get more insight in the prevalence, typeand etiology of cognitive dysfunctioning during treatment with…

Study on the influence of sunitinib and sorafenib on cognitive functioning a cross sectional study (UMCNONCO200901)

To assess the influence of sunitinib and sorafenib on subjective and objective cognitive functioning in patients with metastatic renal cell cancer or a GIST, in order to get more insight in the prevalence, type and etiology of cognitive…

A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR;
targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

The aim of this phase IVI, randomized, open-label study is to compare the efficacy of cabazitaxel versus an AR targeted agent, in patients previously treated with docetaxel and likely to have primary resistance to AR targeted agents.

Increasing pazopanib exposure by splitting intake moments

Based on the above, we propose to perform a prospective pharmacokinetic cross-over trial to test the hypothesis that splitting pazopanib intake moment will increase Cmin and AUC0-24h. In addition, we will show that this is a feasible, safe and cost-…

REduce BlAdder CAncer REcurrence in patients treated for upper urinary tract urothelial carcinoma (REBACARE Trial)

Primary, to show that a single intravesical instillation of chemotherapy immediately before radical surgery for an upper urinary tract (UUT) urothelial carcinoma leads to a 40% reduction in the risk of a subsequent bladder recurrence (urothelial…

A nationwide multicentre, open-label study of six months avelumab maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after at least 4 cycles of first-line platinum-containing chemotherapy and the opportunity to re-treat

This study has been transitioned to CTIS with ID 2024-512975-11-01 check the CTIS register for the current data. To demonstrate benefit of maintenance treatment with avelumab for a maximum of six months avelumab in increasing overall survival (OS)…

68Ga-PSMA-PET/CT and genomic alterations for future selection of patients with metastatic castration resistant prostate cancer (mCRPC) for Radium-223 treatment.

Primary Objective: • To determine the clinical Progression Free Survival (cPFS) in our study cohort of patients with mCRPC and 68Ga-PSMA-PET/CT selected bone-only disease (PET-bone only group). The cPFS will be compared to the cPFS of patients with…